PwPepwise

Galanin

Sleep & Mood

29/30-mer neuropeptide

Galanin is a naturally occurring neuropeptide first isolated from porcine intestine in 1983, consisting of 29 amino acids in most mammals.

§01Summary

Galanin is a naturally occurring neuropeptide first isolated from porcine intestine in 198311, consisting of 29 amino acids in most mammals. It is produced throughout the brain, spinal cord, and peripheral nervous system, where it acts as a chemical messenger that fine-tunes the activity of many other signaling systems — including those involved in mood, sleep, pain, memory, and hormonal regulation. Rather than acting alone, galanin typically works alongside other neurotransmitters such as noradrenaline, serotonin, and GABA, modulating their effects in a region-specific manner16.

Research suggests galanin may play meaningful roles in sleep regulation, with studies indicating that galanin-expressing neurons in the brain's preoptic area appear to promote sleep onset and lower body temperature8. It may also participate in pain processing — levels rise dramatically in sensory nerve cells following injury19 — and in reproductive and parental behavior, where specific galanin neuron populations appear to coordinate complex social responses1,4. Through three identified receptor subtypes (GAL1, GAL2, and GAL3)3, galanin's influence spans conditions including epilepsy, Alzheimer's disease, metabolic regulation, and mood disorders5,7. Human studies are actively emerging across several of these areas.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Galanin is a 29-amino acid neuropeptide (30 amino acids in humans) with a C-terminal amide modification essential for biological activity, first characterized by its sequence Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NH211. It signals through three G protein-coupled receptors — GAL1, GAL2, and GAL3 — each cloned since 19943,6. GAL1 and GAL3 couple primarily to pertussis toxin-sensitive Gi/Go proteins, inhibiting adenylate cyclase and reducing intracellular cAMP6, while GAL2 additionally couples to Gq to stimulate phospholipase C and activate downstream PKC pathways7. These divergent second messenger profiles confer distinct and sometimes opposing physiological consequences depending on receptor subtype expression patterns in target tissues.

Galanin functions predominantly as a neuromodulatory co-transmitter rather than a primary neurotransmitter. It co-localizes extensively with noradrenaline in locus coeruleus A6 neurons, serotonin in dorsal raphe neurons, dopamine in hypothalamic A12 neurons, GABA in arcuate nucleus interneurons, and vasopressin in paraventricular nucleus neurons16. In the ventrolateral preoptic area (VLPO), virtually all galanin-expressing neurons co-express glutamic acid decarboxylase (GAD), indicating co-release of galanin with GABA onto histaminergic tuberomammillary nucleus neurons and onto serotonergic and noradrenergic arousal nuclei, providing a molecular basis for galanin's sleep-promoting actions2. The net inhibitory effect on the ascending arousal system is achieved through both GABA-mediated hyperpolarization and galanin receptor-mediated modulation of neuronal excitability.

In the peripheral nervous system, galanin expression in dorsal root ganglion neurons is dramatically upregulated following axotomy — a classic injury-induced phenotypic switch — with galanin mRNA detectable within 24 hours and levels remaining elevated for at least 60 days post-transection18,19. This injury-state-dependent expression, concurrent with substance P depletion, suggests a coordinated sensory neuron reprogramming relevant to neuropathic pain pathophysiology and implicates GAL1 receptor-mediated inhibition of C-fiber-induced spinal sensitization as a potential analgesic mechanism20.

At the circuit level, distinct subpopulations of galanin-expressing neurons in the medial preoptic area (MPOA) are organized into projection-defined pools analogous to spinal motor neuron pools, with individual subpopulations projecting to different downstream targets and selectively modulating discrete components of parental behavior4. This modular functional architecture — integrating motor, motivational, hormonal, and social behavioral outputs — reflects a broader organizational principle in which galanin acts not as a uniform signal but as a circuit-specific modulator whose net effect is determined by local receptor expression, co-transmitter identity, and presynaptic input state. The galanin peptide family also includes galanin-like peptide (GALP) and alarin, a splice variant of the GALP gene, though the cognate receptors for GALP and alarin remain under active investigation5,7.

§04Evidence & efficacy

Evidence base
302Studies
74Human
105Animal

Galanin's efficacy evidence base is currently grounded in replicated preclinical mechanistic findings across multiple physiological domains, with human efficacy data actively emerging.

Sleep regulation: VLPO galanin neurons appear to causally promote sleep onset and maintenance — optogenetic activation at physiologically relevant low frequencies reliably induced sleep in mice, and chemogenetic activation produced short-latency sleep even in a rodent insomnia model, while inhibition reduced baseline sleep8. This circuit-level role is further supported by anatomical evidence that approximately 80% of VLPO neurons projecting to histaminergic arousal nuclei co-express galanin and GABA, suggesting galanin co-release as a mechanism of arousal suppression2.

Parental and social behavior: Galanin-expressing neurons in the medial preoptic area appear to coordinate multiple components of parental behavior in mice. Optogenetic activation of MPOA galanin neurons suppressed aggression and induced pup-directed grooming in virgin males, while genetic ablation markedly impaired parental responses in both sexes1. Distinct projection-defined subpopulations of these neurons appear to modulate discrete behavioral components including pup retrieval, nursing, and nest building4.

Pain and peripheral nerve injury: Galanin expression in dorsal root ganglion sensory neurons undergoes a dramatic upregulation — approximately 120-fold — following peripheral nerve transection18,19, and intrathecal targeting of GAL1 receptors in rodents modulated C-fiber-induced nociceptive reflexes20, suggesting a role in neuropathic pain signaling that is under active investigation.

Neuroendocrine and reproductive function: Galanin co-expressed in GnRH neurons appears subject to estrogenic regulation and may modulate luteinizing hormone surges relevant to reproductive physiology9. Galanin-positive lumbar spinal neurons appear to modulate ejaculation latency and copulatory patterns in male mice10.

Metabolic effects: Galanin's original characterization included smooth muscle contractile activity and mild hyperglycemia induction in dogs11, with subsequent reviews identifying roles in insulin secretion regulation and energy homeostasis5,7.

§05Safety

Formal safety and tolerability data for exogenous galanin administration in humans is currently an area of active clinical investigation, with no published human trial safety data available in the current evidence base.

From preclinical observations, galanin administration in animals produced mild and sustained hyperglycemia in dogs following systemic exposure11, representing a metabolic signal relevant to future safety monitoring in metabolic or diabetic populations. No overt toxicity or pathological findings were reported in rodent optogenetic or chemogenetic studies8.

A critical technical safety observation emerged from optogenetic studies: high-frequency stimulation (above 8 Hz) of VLPO galanin neurons caused conduction block and paradoxical waking rather than the intended sleep-promoting effect8, highlighting a frequency-dependent boundary that would require careful management in any stimulation-based therapeutic approach.

Galanin's broad co-localization with noradrenergic, serotonergic, dopaminergic, and GABAergic neurotransmitter systems throughout the CNS16 suggests that pharmacological modulation of galanin receptors could potentially influence multiple physiological systems simultaneously, a consideration for future therapeutic development. The three receptor subtypes (GAL1, GAL2, GAL3) mediate distinct downstream signaling cascades3,7, and receptor-selective agents — which remain in active development — will be important for characterizing the safety profile of targeted interventions.

Transportan, a chimeric cell-penetrating peptide incorporating 12 amino acids derived from galanin, demonstrated efficient cellular internalization across multiple cell types with nuclear localization17, though this construct's safety profile is distinct from native galanin itself.

§06History

Galanin was discovered in 1983 by Tatemoto and colleagues, who isolated the 29-amino acid peptide from porcine intestinal extracts using a novel chemical detection method targeting C-terminal amide structures11. The peptide was named for its N-terminal glycine and C-terminal alanine residues. Initial characterization revealed contractile effects on rat smooth muscle and mild hyperglycemia in dogs, foreshadowing its later recognized pleiotropic biology11.

Throughout the mid-to-late 1980s, landmark immunohistochemical mapping studies established galanin's remarkably broad distribution throughout the rat CNS — with high concentrations in the hypothalamus, locus coeruleus, dorsal raphe, and spinal cord dorsal horn — and documented its extensive co-localization with catecholamines, serotonin, GABA, and neuropeptides13,14,16. Peripheral nerve injury studies in 1987–1989 revealed the dramatic upregulation of galanin in dorsal root ganglia following axotomy, establishing galanin as a plasticity-associated peptide in pain circuits18,19.

The molecular era began in 1994 with cloning of the first human galanin receptor (GALR1)6, followed by identification of GALR2 and GALR3, as reviewed in 20003. The VLPO-to-TMN inhibitory circuit was anatomically characterized in 1998, establishing a neurobiological foundation for galanin's role in sleep2. The 2007 and 2015 comprehensive pharmacological reviews consolidated evidence for galanin's relevance to epilepsy, Alzheimer's disease, depression, pain, and metabolic disorders5,7. From 2014 onward, optogenetic and circuit-level studies revealed the functional architecture of MPOA galanin neurons in parental behavior1,4 and VLPO galanin neurons in sleep8, representing the current frontier of galanin research. Investigation of spinal galanin circuits in sexual behavior represents the most recent expansion of the field10.

§07References